- December 16, 2011
Penn Scientist Receives Senior Scholar Award from Ellison Medical Foundation for Aging Research
PHILADELPHIA - James Eberwine, PhD, professor of Pharmacology, at the Perleman School of Medicine at the University of Pennsylvania, has received a Senior Scholar Award from the Ellison Medical Foundation. This supports basic biological research in aging, for $600,000 to be disbursed over the next four years. He is one of 20 investigators to receive this award.
“This grant will enable us to use cutting-edge technologies to assess the contribution of protein synthesis in modulating the aging cell phenotype,” says Eberwine. “One of the unique aspects of these studies is our ability to assess translation of multiple RNAs simultaneously in subregions of aging cells.”
The Ellison Senior Scholar program in Aging is designed to support established investigators to conduct research in the basic biological sciences relevant to age-related diseases and disabilities. It supports the development of new, creative research programs by investigators who may not currently be conducting aging research or who may wish to develop new research programs in aging. The Award stimulates new research, which has rigorous scientific foundations, but which may not be currently funded adequately, because of its perceived novelty, its high risk, or because it is from an area where traditional research interests absorb most funding.
Eberwine’s team will study the translation of messenger RNAs (mRNAs) in dendrites -- the ends of nerve cells -- as a function of aging to ascertain whether dendritic protein synthesis contributes to the cognitive decline often associated with the aging process. This line of work will try to answer if the decrease in neural connections seen in aging can be modulated through regulation of dendritic protein synthesis.
They will look at dendrites in neurons isolated from animal models of aging and isolate mRNAs from individual synapses using a new technique developed in the Eberwine lab. These isolated mRNAs will then be sequenced using next generation nucleic acid sequencers to identify subpopulations of mRNAs that co-localize to individual synapses and are therefore candidates for regulating synaptic function. Translational regulation of this subset of mRNAs will be visualized using novel imaging techniques and algorithms developed to directly quantify this phenomenum. Should protein synthesis of synaptically localized mRNAs be altered during aging the translation of the dysregulated mRNAs will be experimentally manipulated in an effort to assess how aging induced changes in dendritic physiology alters cellular function.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.